Scientists inject one tumor and watch cancer vanish across the body
Why it matters: It proves a single tumor injection can trigger body‑wide cancer immunity, a potential game‑changer for metastatic disease.
- Rockefeller University engineered a more potent CD40 agonist antibody and switched administration from intravenous to intratumoral injection, cutting the severe inflammation seen in earlier attempts.
- Phase‑1 trial (12 patients) published in Cancer Cell reported tumor shrinkage in six participants and complete remission in two, with even non‑injected tumors shrinking, indicating a systemic immune effect.
- Jeffrey V. Ravetch highlights the unexpected whole‑body response, suggesting this method may finally overcome the toxicity and limited efficacy that plagued previous CD40‑based therapies.
A redesigned CD40 agonist antibody, delivered directly into a tumor, sparked systemic tumor loss in a phase‑1 trial—half the 12 patients saw shrinkage and two achieved complete remission, reviving hope for immunotherapy that works beyond the injection site.
